The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity

Life Sciences
Grazyna WójcickaJerzy Bełtowski

Abstract

The present study was designed to examine the effect of sulphonylureas, glimepiride (GM) and glibenclamide (GB), on paraoxonase 1 (PON1) and platelet activating factor acetylohydrolase (PAF-AH) activity in normal and streptozotocin (STZ)-induced (50 mg/kg) diabetic rats. In treated groups, glimepiride (0.1 mg/kg) or glibenclamide (2 mg/kg) was given orally for 4 weeks. A PON1 and PAF-AH activity were estimated by spectrophotometric method. Hyperglycemia was accompanied by a significant decrease in plasma PON1 activity toward paraoxon (P < 0.001) and phenyl acetate (P < 0.01) and increase in plasma PAF-AH activity (P < 0.01). In STZ-induced diabetic rats the administration of both GM and GB had no effect on plasma PON1 activity but reversed elevated plasma PAF-AH activity (GM: P < 0.05, GB: P < 0.01). In non-diabetic rats after either GM or GB administration the decreased PON1 activity in the plasma was observed (GM: P < 0.001, GB: P < 0.05), but plasma PAF-AH activity remained unchanged. Both GM and GB had no effect on total plasma antioxidant capacity in diabetic and control treated groups. Additionally, both drugs increased PON1 activity toward phenyl acetate in the liver, in diabetic rats (GM: P < 0.05, GB:ns) as well as in ...Continue Reading

References

Jul 29, 1991·FEBS Letters·M I MacknessP N Durrington
Jul 20, 1990·Biochimica Et Biophysica Acta·B N PatelP N Durrington
Jan 1, 1990·Methods in Enzymology·H Esterbauer, K H Cheeseman
Jun 1, 1994·Current Opinion in Lipidology·I HardardóttirK R Feingold
Oct 1, 1993·Diabetes Research and Clinical Practice·J SatoN Sakamoto
Jun 1, 1994·The Journal of Clinical Investigation·G AmbrosioM Triggiani
Jul 1, 1996·Diabetes Research and Clinical Practice·P SmitsT Thien
Jan 1, 1998·Journal of Biochemical and Molecular Toxicology·M C GonzalvoA Pla
Feb 12, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·A AyubP N Durrington
May 31, 2001·Clinical and Experimental Pharmacology & Physiology·N S FarrarG A Johnston
Mar 20, 2003·Molecular Pharmacology·Cédric GouédardYannick Morel
Mar 15, 2005·The Journal of Biological Chemistry·Shuichi FukuenIichiro Shimomura
Apr 13, 2005·Atherosclerosis·Bianca FuhrmanMichael Aviram
Aug 23, 2005·Biochimica Et Biophysica Acta·Sonia-Athina P KarabinaNalini Santanam
Jan 21, 2006·Journal of Cardiovascular Pharmacology·Shao-cai HongZhi-hong Wu
Sep 12, 2006·Free Radical Biology & Medicine·Anne Negre-SalvayreRobert Salvayre
Dec 23, 2006·Clinical and Experimental Pharmacology & Physiology·Jeroen van WijkJorge Joven
Jan 11, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Amy N MacRitchieDiana M Stafforini
Dec 1, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Yanbo FanNanping Wang
Mar 25, 2008·Free Radical Biology & Medicine·Orit RozenbergTony Hayek

❮ Previous
Next ❯

Citations

Aug 27, 2011·Antioxidants & Redox Signaling·Zhi-Gang SheDe-Pei Liu
Aug 17, 2012·Journal of Lipid Research·Daniel S KimGail P Jarvik
Nov 26, 2010·Biochemical Pharmacology·Lucio G CostaClement E Furlong
Jun 18, 2014·Journal of Enzyme Inhibition and Medicinal Chemistry·Ayla Solmaz AvcikurtFeray Kockar
May 17, 2008·Life Sciences·Zhifang FuChaoshu Tang
Jan 28, 2017·Journal of Diabetes and Metabolic Disorders·Zakariya M Al Aamri, Badreldin H Ali
Feb 7, 2018·Naunyn-Schmiedeberg's Archives of Pharmacology·Carlos Moya, Salvador Máñez
Mar 20, 2014·Jundishapur Journal of Natural Pharmaceutical Products·Mohammad Reza TakaeidiZahra Mansourzadeh

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.